Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Daniel Heng, MD, MPH, FRCPC
Advertisement
Articles by Daniel Heng, MD, MPH, FRCPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
How should ctDNA guide adjuvant therapy after perioperative EV?
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5